Interleukin 2 News and Research

RSS

Neuroticism can be good for health under certain circumstances

Under certain circumstances neuroticism can be good for your health, according to a University of Rochester Medical Center study showing that some self-described neurotics also tended to have the lowest levels of Interleukin 6 (IL-6), a biomarker for inflammation and chronic disease.

14 Nov 2012

Study explores impact of IL1β on brain function alterations associated with schizophrenia

There are a growing number of clues that immune and inflammatory mechanisms are important for the biology of schizophrenia. In a new study in Biological Psychiatry, Dr. Mar Fatjó-Vilas and colleagues explored the impact of the interleukin-1β gene (IL1β) on brain function alterations associated with schizophrenia.

2 Nov 2012

Researchers decode software instructions that drive 3 different forms of acute lymphoblastic leukemia

30 Oct 2012

Scientists decode epigenetic programming of three virulent forms of acute lymphoblastic leukemia

A team of national and international researchers, led by Weill Cornell Medical College scientists, have decoded the key "software" instructions that drive three of the most virulent forms of acute lymphoblastic leukemia (ALL). They discovered ALL's "software" is encoded with epigenetic marks, chemical modifications of DNA and surrounding proteins, allowing the research team to identify new potential biomarkers and therapeutic targets.

29 Oct 2012

Interim results from CEL-SCI's Multikine Phase III study on head and neck cancer

CEL-SCI Corporation announced today that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy by an Independent Data Monitoring Committee (IDMC) raised no safety concerns.

23 Oct 2012

$Ustekinumab success in refractory Crohn’s disease$

Ustekinumab success in refractory Crohn’s disease

Patients with Crohn’s disease who have failed to respond adequately to anti–tumor necrosis factor treatment may benefit from the monoclonal antibody ustekinumab, results of a double-blind, placebo-controlled trial suggest.

22 Oct 2012

Fungal exposure in homes could increase risk of sarcoidosis

People who are exposed to mold in their homes could be at an increased risk for sarcoidosis, a chronic inflammatory lung disease. Researchers from Sweden and Slovenia tested 62 nonsmoking patients with sarcoidosis, 34 of whom had extrapulmonary manifestations (EPM).

22 Oct 2012

ACT TIL therapy effective in treating metastatic melanoma

Researchers at Moffitt Cancer Center have carried out a clinical trial in which patients with metastatic melanoma were given chemotherapy and an immunotherapy of adoptive cell transfer (ACT) with tumor infiltrating lymphocytes (TIL).

19 Oct 2012

Ustekinumab shows positive results in decreasing debilitating effects of Crohn's Disease

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn's Disease, according to researchers at the University of California San Diego, School of Medicine.

18 Oct 2012

Cytokine levels altered in FEP, schizophrenia patients

Levels of certain cytokines are altered in patients with first-episode psychosis and patients with schizophrenia, research shows.

17 Oct 2012

Companionship can reduce nerve-related pain

Companionship has the potential to reduce pain linked to nerve damage, according to a new study.

16 Oct 2012

IL-36 might be a useful therapeutic target in treatment of psoriasis

Psoriasis is a chronic inflammatory skin disorder that affects approximately 2% of the world's population. A group of inflammatory molecules known as interleukins activate an immune response that causes itchy skin, but it is unclear how the skin cells and immune cells communicate.

16 Oct 2012

Rheumatoid arthritis treatment foiled by gum disease

Periodontal disease may reduce the efficacy of tumor necrosis factor inhibitor treatment in patients with rheumatoid arthritis, preliminary research suggests.

15 Oct 2012

Regulatory B cells may provide effective treatment for severe autoimmune diseases

Reproducing a rare type of B cell in the laboratory and infusing it back into the body may provide an effective treatment for severe autoimmune diseases such as multiple sclerosis or rheumatoid arthritis, according to researchers at Duke University Medical Center.

15 Oct 2012

Highlights of Mount Sinai research at Neuroscience 2012

Researchers from Mount Sinai School of Medicine are presenting important discoveries on the involvement of the immune system and dopamine cells in the onset of depression at Neuroscience 2012, the Society for Neuroscience's 42nd annual meeting on October 13 -17 in New Orleans, and are available for interviews.

15 Oct 2012

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract and a Phase 2 option from the National Cancer Institute (NCI) valued up to $1,683,503.

8 Oct 2012

Modulating immune response to injury could accelerate regeneration of peripheral nerves

Modulating immune response to injury could accelerate the regeneration of severed peripheral nerves, a new study in an animal model has found. By altering activity of the macrophage cells that respond to injuries, researchers dramatically increased the rate at which nerve processes regrew.

4 Oct 2012

Omega-3 fatty acid supplements could slow key biological process linked to aging

Taking enough omega-3 fatty acid supplements to change the balance of oils in the diet could slow a key biological process linked to aging, new research suggests.

2 Oct 2012

OncoSec establishes UW as second enrolling site for OMS-I100 Phase II metastatic melanoma trial

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that it has established the University of Washington (UW) as the second enrolling site for its Phase II metastatic melanoma clinical trial (OMS-I100).

25 Sep 2012

Interleukin-6 could affect hunger and satiety

Researchers at the Sahlgrenska Academy, University of Gothenburg, Sweden, have identified a molecule in the immune system that could affect hunger and satiety. The researchers hope that new treatments for obesity will benefit from this finding.

24 Sep 2012

Interleukin 2 News and Research

Neuroticism can be good for health under certain circumstances

Study explores impact of IL1β on brain function alterations associated with schizophrenia

Researchers decode software instructions that drive 3 different forms of acute lymphoblastic leukemia

Scientists decode epigenetic programming of three virulent forms of acute lymphoblastic leukemia

Interim results from CEL-SCI's Multikine Phase III study on head and neck cancer

Ustekinumab success in refractory Crohn’s disease

Fungal exposure in homes could increase risk of sarcoidosis

ACT TIL therapy effective in treating metastatic melanoma

Ustekinumab shows positive results in decreasing debilitating effects of Crohn's Disease

Cytokine levels altered in FEP, schizophrenia patients

Companionship can reduce nerve-related pain

IL-36 might be a useful therapeutic target in treatment of psoriasis

Rheumatoid arthritis treatment foiled by gum disease

Regulatory B cells may provide effective treatment for severe autoimmune diseases

Highlights of Mount Sinai research at Neuroscience 2012

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Modulating immune response to injury could accelerate regeneration of peripheral nerves

Omega-3 fatty acid supplements could slow key biological process linked to aging

OncoSec establishes UW as second enrolling site for OMS-I100 Phase II metastatic melanoma trial

Interleukin-6 could affect hunger and satiety

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News